CHGA and neoplasm: Additionally, combining NLR with other biomarkers such as chromogranin A, circulating tumor cells (CTCs), or transcriptome profiles might improve prognostic accuracy in specific patient populations, notably in gastrointestinal malignancies and NSCLC (39, 40).